2020
Considerations on equity in management of end-stage kidney disease in low- and middle-income countries
Van Biesen W, Jha V, Abu-Alfa AK, Andreoli SP, Ashuntantang G, Bernieh B, Brown E, Chen Y, Coppo R, Couchoud C, Cullis B, Douthat W, Eke FU, Hemmelgarn B, Hou FF, Levin NW, Luyckx VA, Morton RL, Moosa MR, Murtagh FEM, Richards M, Rondeau E, Schneditz D, Shah KD, Tesar V, Yeates K, Garcia G. Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney International Supplements 2020, 10: e63-e71. PMID: 32149010, PMCID: PMC7031686, DOI: 10.1016/j.kisu.2019.11.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEnd-stage kidney diseaseMiddle-income countriesKidney diseaseHealth systemFull health potentialOverall health care spendingHealth care spendingTherapy programHealth potentialCare spendingDiseaseDelivery modelEquitable provisionEquitable implementationKRTPrevalenceIncidenceIssues of availabilitySuggest areas
2011
Chloride Modulates GSTZ1 Haplotype‐dependent Inactivation by Dichloroacetate
Li W, Gu Y, Langaee T, Hines R, Stacpoole P, James M. Chloride Modulates GSTZ1 Haplotype‐dependent Inactivation by Dichloroacetate. The FASEB Journal 2011, 25: 813.2-813.2. DOI: 10.1096/fasebj.25.1_supplement.813.2.Peer-Reviewed Original ResearchGSTZ1 activityLiver cytosolHuman liver cytosolCongenital lactic acidosisHaplotype-dependent mannerLactic acidosisGSTZ1 protein expressionGSTZ1 haplotypeMM dichloroacetateDCA pharmacokineticsProtein expressionDichloroacetateHr incubationGSTZ1SubjectsKRTIndividualsHeterozygous individualsInactivationAcidosisPharmacokineticsCancerDosesClearance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply